Fulcrum Therapeutics, Inc. (FULC) Form 10-Q — Jul 30, 2026

Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease after receiving FDA feedback indicating heightened concerns regarding the drug's benefit-risk profile and no viable regulatory path. In response, the company implemented a restructuring plan on May 31, 2026, reducing its workforce by approximately 85% from 57 to nine employees and ceasing all research and development activities to preserve capital. For the six months ended June 30, 2026, the company reported a net loss of $45.1 million, compared to a loss of $35.0 million in the prior-year period, driven by $4.3 million in restructuring expenses and $5.1 million in impairment charges.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.